A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2024
This article has no abstract
Epistemonikos ID: 11de7bf5e8d61c3f4b2e92c66dabb9d35b3ec58e
First added on: Jan 17, 2025